Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Biovitrum, Wyeth Extend Supply Pact | Contract Pharma

What are you searching for?

Sign in
Breaking News, Collaborations & Alliances

Biovitrum, Wyeth Extend Supply Pact

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Biovitrum AB and Wyeth have extended their ReFacto supply agreement through December 31, 2015. Biovitrum will continue to be the sole producer of drug substance for Wyeth for ReFacto, as well as Xyntha/ReFacto AF, the successor products, and will continue to receive royalties from Wyeth’s global sales. Biovitrum’s co-promotion rights in the Nordic region remain unchanged. Biovitrum’s total revenues from the ReFacto business amounted to $143 million in 2007. ReFacto, Xyntha and ReFacto AF are recombinant protein drugs for hemophilia A.

“We are very pleased to be able to announce the prolongation of our long and successful collaboration with Wyeth. The agreement enables us to together provide the new improved Xyntha and ReFacto AF internationally, and to improve the lives of hemophilia patients.” commented Martin Nicklasson, chief executive officer of Biovitrum. “The agreement validates our biotechnology therapeutic production capabilities and expertise.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters